Investing In Health Stocks - How Policy Clarity Is Opening Doors

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Seeking Alpha • Nov 11, 2025

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Seeking Alpha • May 30, 2025

IDNA: The Cutting Edge Of Medical Science Is A Risky Investment

The iShares Genomics Immunology and Healthcare ETF is invested in 49 companies involved in genomics, immunology and bioengineering. Compared with the biotechnology benchmark IBB, IDNA has value characteristics, but has greatly underperformed, losing over 20% since its inception. Among genomics-focused ETFs, PBE offers a relatively safer choice with better performance and lower volatility.

Seeking Alpha • Apr 20, 2025

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Seeking Alpha • Feb 25, 2025

Disruptive Theme of the Week – Breakthroughs in Medicine

Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.

ETF Trends • Nov 21, 2024

IDNA: Healthcare Dashboard For February

This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks cheaper than their peers in February.

Seeking Alpha • Feb 18, 2024

Disruptive Tech Theme of the Week: 7 Disruptive Themes for 2024

To use a holiday analogy, I have been checking lists and checking them twice to figure out which of next year's top disruptive investment themes are likely to be nice.

ETF Trends • Dec 18, 2023

VettaFi Voices On: Accessing Disruptive Innovation

Good Morning, VettaFi Voices! Disruptive innovation is a popular topic, and it encompasses everything from bitcoin and cryptocurrency to electric vehicles to artificial intelligence.

ETF Trends • Nov 17, 2023

IDNA: Continues To Underperform, But With Long-Term Potential

I rate IDNA a Hold due to its focus on biotech stocks with long-term growth potential in a rapidly growing healthcare industry. Despite impressive growth since its inception in 2019, IDNA has experienced a downward trajectory since 2021, with its current price lower than at inception. The healthcare industry is predicted to be the fastest growing industry in the US in 2023, with a 15% growth rate expected by 2027, making it a profitable long-term investment space.

Seeking Alpha • Jun 8, 2023

IDNA: Thematic Biotechnology Index Fund Only Suitable For The Long Run

Genomic revolution and pharmacogenomics have strong growth prospects that may enable the iShares Genomics Immunology and Healthcare ETF biotech portfolio to generate supernormal growth. In order to enable retail investors to benefit from this technological advancement in the field of DNA, investors can think of options like IDNA. Since its creation, IDNA's price has more than doubled within a span of almost 39 months. However, since September 2022, price has been in a steady decline.

Seeking Alpha • Jun 7, 2023